Monday, December 17, 2012
Biotron Ltd., of Sydney, Australia, said it expects to deliver preliminary data from a Phase Ib/IIa study of lead HIV drug, BIT225, in the March quarter of 2013. BIT225 is designed to specifically target HIV in reservoir cells to stop the ongoing cycle of infection in the body.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.